IP Library Granted Patent US 9,823,250
Granted Patent B2
US 9,823,250 · App. 15/442,639 · Granted Nov 21, 2017

Crystal structures of human Torsin-A and methods of determining and using the same

Inventors: Thomas U. Schwartz (Brookline, MA); F. Esra Demircioglu (Boston, MA); Brian A. Sosa-Alvarado (Cambridge, MA)
Assignee: Massachusetts Institute of Technology
G01N33/573C12N9/14C12Y306/04C40B30/02G01N23/20G06F19/16G06F19/18G01N2333/914G01N2500/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,823,250
App. No.
15/442,639
Granted
Nov 21, 2017
Kind
B2
Abstract

A protein composition including TorsinA or TorsinA mutant, LULL1, and a nanobody obtained by immunization using TorsinA and LULL1 is used to grow complex crystals, and three dimensional structures are determined using x-ray data of the crystals. A screening platform is built based on the determined three dimensional structures for designing a drug lead to cure dystonia.

Claims (8)

1. A protein composition, comprising: a target protein; a modulator of the target protein; and a nanobody comprising a polypeptide as set forth in SEQ ID NO: 5 or a portion thereof, wherein said nanobody or said portion thereof specifically binds to at least one of the target protein and the modulator.

2. The protein composition of claim 1 , wherein the target protein is TorsinA, a mutant of TorsinA, or a portion thereof.

3. The protein composition of claim 2 , wherein the target protein comprises an amino acid sequence as set forth in at least one of SEQ ID NO: 1-3 or a portion thereof.

4. The protein composition of claim 1 , wherein the modulator is LULL1 or a portion thereof.

5. The protein composition of claim 4 , wherein the modulator comprises the amino acid sequence set forth in the SEQ ID NO: 4.

6. The protein composition of claim 1 , wherein the nanobody is specific for a complex comprising the target protein and the modulator.

7. The protein composition of claim 6 , wherein the nanobody is obtained by immunization using the target protein comprising the amino acid sequence set forth in the SEQ ID NO: 2 and the modulator comprising the amino acid sequence set forth in the SEQ ID NO: 4.

8. The protein composition of claim 7 , wherein the target protein comprises the amino acid sequence set forth in at least one of SEQ ID NO: 1-3 or a portion thereof, the modulator comprises the amino acid sequence set forth in the SEQ ID NO: 4 or a portion thereof, the nanobody comprises the amino acid sequence set forth in the SEQ ID NO: 5 or a portion thereof, and the protein composition is co-expressed, and optionally purified together.

Assignments (2)
CONFIRMATORY LICENSE Recorded Mar 24, 2017
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042086/0710 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2017
From: SCHWARTZ, THOMAS U.; DEMIRCIOGLU, F. ESRA; SOSA-ALVARADO, BRIAN A.
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 041464/0001 →
Continuity (3)
Provisional Application 62330683 · May 2, 2016
Provisional Application 62299699 · Feb 25, 2016
Related Publication 20170248601A1 · Aug 31, 2017